1-9 of 9
Leo I. Gordon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A. Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-19-3239
Published: 15 July 2020
View articletitled, Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Open the PDF for Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View articletitled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael Harb, Leo I. Gordon, Robert Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, Sharon Horton, Thorsten Graef, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (5): 1059–1066.
https://doi.org/10.1158/1078-0432.CCR-15-0624
Published: 29 February 2016
View articletitled, A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Open the PDF for A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma in another window
Includes: Supplementary data
Journal Articles

Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata

Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, Leo I. Gordon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4755–4768.
https://doi.org/10.1158/1078-0432.CCR-10-0883
Published: 29 September 2010
View articletitled, Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata
Open the PDF for Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata in another window
Journal Articles

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Andrew M. Evens, William G. Spies, Irene B. Helenowski, David Patton, Stewart Spies, Borko D. Jovanovic, Sarah Miyata, Elizabeth Hamilton, Daina Variakojis, Jun Chen, Louie Naumovski, Steven T. Rosen, Jane N. Winter, Richard A. Miller, Leo I. Gordon
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6462–6471.
https://doi.org/10.1158/1078-0432.CCR-09-0905
Published: 14 October 2009
View articletitled, The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Open the PDF for The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

Savita Bhalla, Sriram Balasubramanian, Kevin David, Mint Sirisawad, Joseph Buggy, Lauren Mauro, Sheila Prachand, Richard Miller, Leo I. Gordon, Andrew M. Evens
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3354–3365.
https://doi.org/10.1158/1078-0432.CCR-08-2365
Published: 18 May 2009
View articletitled, PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
Open the PDF for PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells in another window
Includes: Supplementary data
Journal Articles

Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent

Andrew M. Evens, Sheila Prachand, Bo Shi, Mary Paniaqua, Leo I. Gordon, Ronald B. Gartenhaus
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (4): 1481–1491.
https://doi.org/10.1158/1078-0432.CCR-1058-03
Published: 20 February 2004
View articletitled, Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent
Open the PDF for Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent in another window
Journal Articles

Arsenic Trioxide Cytotoxicity in Steroid and Chemotherapy-resistant Myeloma Cell Lines: Enhancement of Apoptosis by Manipulation of Cellular Redox State

Ronald B. Gartenhaus, Sheila N. Prachand, Mary Paniaqua, Yuyu Li, Leo I. Gordon
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (2): 566–572.
Published: 01 February 2002
View articletitled, Arsenic Trioxide Cytotoxicity in Steroid and Chemotherapy-resistant Myeloma Cell Lines: Enhancement of Apoptosis by Manipulation of Cellular Redox State
Open the PDF for Arsenic Trioxide Cytotoxicity in Steroid and Chemotherapy-resistant Myeloma Cell Lines: Enhancement of Apoptosis by Manipulation of Cellular Redox State in another window
Journal Articles

Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 90Y-labeled Anti-CD20 Monoclonal Antibody

Gregory A. Wiseman, Christine A. White, Thomas E. Witzig, Leo I. Gordon, Christos Emmanouilides, Andrew Raubitschek, Nalini Janakiraman, John Gutheil, Russell J. Schilder, Stewart Spies, Daniel H. S. Silverman, Antonio J. Grillo-López
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3281s–3286s.
Published: 01 October 1999
View articletitled, Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 90Y-labeled Anti-CD20 Monoclonal Antibody
Open the PDF for Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 90Y-labeled Anti-CD20 Monoclonal Antibody in another window